Research Article
Analysis of Glomerular IgG Subclasses Switch in Idiopathic Membranous Nephropathy Classified by Glomerular Phospholipase A2 Receptor Antigen and Serum Antibody

Hao-yuan Cui, Chao Li, Hang Li, Yu-bing Wen, Lin Duan, Yan Li, Xi-wei Yan, Yu-ting Hu, Li-meng Chen, and Xue-mei Li

Nephrology Division, Peking Union Medical College Hospital, Beijing 100730, China

Correspondence should be addressed to Hang Li; lihang9@hotmail.com

Received 22 March 2021; Accepted 10 August 2021; Published 30 August 2021

Academic Editor: Alexandra Scholze

Copyright © 2021 Hao-yuan Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The role of IgG subclass in idiopathic membranous nephropathy (IMN) was unclarified. Recent study found IgG subtype switches from IgG1 to IgG4 in the early pathological stage in IMN. The profile of IgG subclass in phospholipase A2 receptor- (PLA2R-) related and PLA2R-unrelated IMN was unrevealed. Our study is aimed at testifying whether IgG subclass switch existed in PLA2R-related and PLA2R-unrelated IMN, respectively.

Methods. Our study retrospectively enrolled 157 Chinese patients with biopsy-confirmed IMN between September 2017 and November 2019. We measured glomerular PLA2R antigen and serum anti-PLA2R antibody to classify the patients into PLA2R-related (n = 132) and PLA2R-unrelated (n = 25) subgroup. We evaluated glomerular IgG subclass by immunofluorescence (IF) predominance. Our study defined IgG subclass deposition as predominant if the IF score was higher than the other three and ≥1 +, or as codominant if the IF intensity was equal to any other and ≥1 +. We explored the relationship between IF predominance of glomerular IgG subtype and electron microscopic (EM) stages of IMN.

Results. We did not find statistical difference of predominant or codominant rate (pre/co-rate) among EM stages in any subclass (P > 0.05). Pre/co-rate of IgG3 linearly associated with EM stage in total and PLA2R-related subgroup (P = 0.044, P = 0.013). PLA2R-related subgroup showed higher IgG4 intensity (2.1 ± 0.6 vs. 1.6 ± 0.7, P = 0.001) and pre/co-rate of IgG4 in stage 1 (97% vs. 57%, P = 0.015) than PLA2R-unrelated group. We found no difference of IgG subclass pre/co-rate in different EM stages or linear association between pre/co-rate of IgG1, IgG2, IgG4, and EM stages (P > 0.05). Conclusions. Pre/co-rate of IgG3 declined with EM stage in total and PLA2R-related subgroup. We did not find IgG subclass switches from IgG1 to IgG4 in either IMN patients or subgroups.

1. Introduction

Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome among the adult population [1, 2]. M-type phospholipase A2 receptor (PLA2R), the dominant autoantigen of IMN with mostly specific IgG4 autoantibodies, has been studied widely since discovered in 2009 [3]. The exact role of different IgG subclass in IMN remained elusive. In 2013, Huang et al. reviewed pathological data in 157 membranous nephropathy patients. They implied major IgG subtype deposited in glomerular changed from IgG1 to IgG4 during the process of IMN [4]. However, the IgG subclass switching was observed in some but not all studies. Hihara et al. suggested IgG1 might dominate in situ while anti-PLA2R antibody was not shown by analyzing a small group of PLA2R-related IMN [5]. In 2016, Kattah et al. revealed IgG4 predominated in 5 recurrent PLA2R-related IMN and declared no subclass switch [6]. Huang et al. failed to test circulating antibody or glomerular antigen of IMN. It was unclear whether the IgG subtype switching was present in subgroup stratified by different antigen.

In this study, we investigated the IgG subclass distribution of PLA2R-related and PLA2R-unrelated IMN in different EM stages. To verify the IgG subclass switching in IMN,
we illustrate the profile of IgG subtype in IMN and further investigate the IgG subclass switching in PLA2R-related and PLA2R-unrelated IMN.

2. Materials and Methods

2.1. Study Population. Our study retrospectively enrolled 157 patients with biopsy-proven IMN hospitalized in the Peking Union Medical College Hospital (PUMCH) between September 2017 and November 2019. The study was approved by the PUMCH ethical committees (No. S-K014). The inclusion criteria were as follows: diagnosis of IMN confirmed by renal biopsy; serum anti-PLA2R antibody was detected at the time of diagnosis. Patients with known secondary MN, such as hepatitis B/C virus infection, drug/toxin exposure, autoimmune disease, or malignancy, were excluded (Figure 1). We collected clinical data from medical records at the time of diagnosis, including age at biopsy, gender, serum creatinine (Scr), albumin (Alb), and 24h urine protein (24hUP).

2.2. Detection of Circulating Anti-PLA2R Ab. We collected the serum for anti-PLA2R antibody assay before treatment and performed with enzyme linked immunosorbent assay (ELISA) kit (EUROIMMUN, Lübeck, Germany) according to the manufacturer’s instruction. We set up the cut-off value of the positive result as above 14 relative light units per milliliter (RU/mL).

2.3. Kidney Biopsy. We conducted standard kidney biopsy [7, 8]. Tissue for light microscopy was routinely stained with hematoxylin and eosin, Masson, Jones methenamine silver, and periodic acid-Schiff reagent. Specimen for immunofluorescence (IF) was cut at 5 μm in freezing microtome. We performed direct IF with fluorescein isothiocyanate- (FITC-) conjugated antibodies to human IgG, IgA, IgM, C3, C4, C1q, κ, and λ-light chains, fibrinogen, and albumin (Dako, Copenhagen, Denmark) for 30 minutes in 37°C. We used indirect IF to detect IgG subclass in situ. The slice was conducted with 1:50 mouse anti-human IgG1, IgG2, IgG3, and IgG4 (Invitrogen, Camarillo, CA) at 4°C overnight, followed by 1:25 FITC-conjugated rabbit anti-mouse IgG (Dako, Copenhagen, Denmark) at 37°C 2h. Renal tissue for EM was performed according to the standard protocol [9].

We semiquantitatively scored IF staining from 0 to 3 + (0 negative, 1 + weak staining, 2 + moderate staining, and 3 + strong staining). The predominant deposition was defined if the score was higher for one IgG subclass than the other three and ≥1 +. IF staining was categorized as codominant if more than one IgG subclasses were equal in intensity and ≥1 +. The EM stage was classified according to the Ehrenreich and Churg classification [9]. We divided different EM stages into 4 groups: 1, 2, 3, and 4. Stage 1 included EM stages 1 and 1-2. Stage 2 included EM stages 2 and 2-3. EM stage 3-4 and stage 4 were classified into stage 4 for its immune complex was started to reabsorb.

2.4. Glomerular PLA2R Ag Expression. We processed PLA2R staining by indirect IF using mouse anti-human PLA2R Ab (Sigma, Gallen, Switzerland) at a dilution of 1:200 overnight at room temperature, followed by FITC-conjugated rabbit anti-mouse IgG (Dako, Copenhagen, Denmark) at a dilution of 1:25 at 37°C for 2h.

2.5. Definition of PLA2R-Related and PLA2R-Unrelated IMN. PLA2R-related IMN was defined as positive circulating antibody to PLA2R by ELISA and/or glomerular PLA2R antigen by IF. PLA2R-unrelated IMN was defined if both serum antibody and glomerular antigen exposure were negative.

2.6. Statistical Analyses. Clinical parameters were expressed as medians and quartiles (P25, P75) for nonnormally distributed continuous variables. The Mann-Whitney U test was performed for comparison between two subgroups of continuous variables. Differences in categorical variables were analyzed using the Chi-squared test or Fisher's exact when appropriate. Trends were explored by linear-by-linear association test. All tests were two-sided and P values < 0.05 were considered statistically significant. Statistical analyses were performed by the SPSS statistical software package, version 20.0 (SPSS Inc., Chicago, IL).

3. Results

3.1. Clinical and Pathological Characteristics of Total IMN Patients. Among the 157 patients with IMN, 57% (n = 89) were male and 43% (n = 68) were female, with a median age of 51 (38, 58) years at the time of diagnosis. The medium Alb was 27 (23, 32) g/L, the medium 24hUP was 4.75 (2.21, 7.4) g/L, and the medium Scr was 72 (61, 86.5) μmol/L. Among them, intensities of IgG1, IgG2, IgG3, and IgG4 were 1.4 ± 0.7, 0.5 ± 0.7, 1.0 ± 0.8, and 2.0 ± 0.6, respectively.

3.2. Clinical and Pathological Data of PLA2R-Related and PLA2R-Unrelated Subgroup

3.2.1. Serology and Histology of PLA2R. The clinical and pathological data of two subgroups were shown in Table 2. The positive rate of PLA2R was 56% (88/157) in circulation and 76% (119/157) in situ (see Table 3). Patients were divided into PLA2R-related (n = 132, 84%) and PLA2R-unrelated (n = 25, 16%) subgroup. The differences showed no statistical significance of age, gender, Alb, 24hUP, and Scr of different EM stages between two subgroups (Table 2). The anti-PLA2R antibody titers of different stages in serum-positive patients showed no statistical significance.

3.2.2. Fluorescence Intensity of IgG Subclass Staining. IF staining of IgG subclass was illustrated in Figure 2. PLA2R-related subgroup showed higher glomerular deposition of IgG4 (2.1 ± 0.6 vs. 1.6 ± 0.7, P = 0.001) than PLA2R-unrelated subgroup. Among different EM stage, the intensity of the IgG4 deposit was much higher in stage 4 of PLA2R-related subgroup than that of PLA2R-unrelated subgroup (2.4 ± 0.5 vs. 1.3 ± 1.0, P = 0.032) (see Figure 3).

3.2.3. IgG Predominant/Codominant Distribution and Trend Exploration. Pre/codeposition of IgG subclass in different EM stage was illustrated in Figure 4. In PLA2R-related
subgroup, pre/co-rate of IgG4 was higher in stage 1 (97% vs. 57%, \( P = 0.015 \)), and pre/co-rate of IgG3 was lower in stage 3 (8% vs. 75%, \( P = 0.027 \)) than that in PLA2R-unrelated subgroup (see Figures 4(d) and 4(c)). The pre/co-rate of IgG3 showed a linear association with EM stage in PLA2R-related group (see Table 4).

### 4. Discussion

The main result of our study was IgG3 showed a declining trend from EM stages 1 to 4 in PLA2R-related subgroup. There were three possible explanations. Firstly, more evidences indicated that IgG3 played a key role in the early stage of immune diseases. Previous study delineated that human body produced a fixed order of IgG subclass in immune response, namely, IgG3 > IgG1 > IgG2 > IgG4 [10]. Elevated IgG3 in serum might predict the initial stage of an immune disease, such as acute rheumatic fever [11]. IMN incidence presents an increase trend [12] and is associated with high level of PM 2.5 exposure [13]. Researchers speculated environmental hazards acted B cell to produce specific antibody against PLA2R-expressing on both alveolar epithelial cell and podocyte [14]. In 2012, Debiec et al. reported an early recurrent PLA2R-related IMN caused by exclusively IgG3 [15]. Our data present a similar result in a homogeneous cohort and added another brick to the role of IgG3 in early stage of PLA2R-related IMN.

Secondly, our result fitted the established phenomenon of epitope spreading in PLA2R-related IMN [16]. The theory was described as cysteine-rich (CysR) exposed in the early stage of PLA2R-related IMN, then spread to C-type lectin domain 1 (CTLD1) and C-type lectin domain 1 (CTLD7) to enhance the immune response. IgG1, 2, 3, 4 combined CysR and CTLD1 while IgG4 only acted on CTLD7 [16].
Thirdly, some researchers detected IgG1 and IgG3 sub-type of PLA2R-related IMN but IgG4 were absent [17]. Although IgG4 was the predominant Ig of PLA2R-related IMN in situ, few evidences elucidated its pathogenicity. Thus, our result indicated that IgG3 might play a potent role in the early stage of PLA2R-related IMN.

We did not discover IgG subclass switch from IgG1 to IgG4 in IMN as reported by Huang et al. [4]. The pre/co-rate of IgG4 in EM stage 1 was obviously high in our study than that in Huang et al.’s study (89% vs. 55%). Three possible reasons might contribute to the discrepancy. Firstly, the different inclusion criteria could bring selection bias. The clinical data were not provided in Huang et al.’s work. We failed to analyze the difference of two study populations. Secondly, the discrepancy might come from the distribution of EM stages between two studies ($\chi^2 = 24.85, P < 0.001$). The difference mainly existed in early stages ($n = 38, 24.2\%$ vs. $n = 58, 50.9\%$ in stage 1) and middle stages ($n = 100, 63.7\%$ vs. $n = 39, 34.2\%$ in stages 2-3) between our data and Huang et al.’s. Thirdly, the definition of early EM stage (stage 1) was different. Huang et al. emphasized they separated the “true” stage 1 by redefining it as electronic dense absent between subepithelial. Our cohort might include more advanced patients of stage 1. However, the pre/co-rate of IgG4 was comparable between stages 1 and 2 (89\% vs. 94\%) in our study, even in PLA2R-related group that was higher of stage 1 than that of stage 2 (97\% vs. 95\%). It was unlikely that the discrepancy of EM stage definition gave rise to the gap on pre/co-rate of IgG4 in stage 1 between two studies. We assumed the discrepancy just reflected ethnic differences [18]. Huang et al. provided no serum or pathological profiles of PLA2R. To further explore IgG subtype switch of different antigens, we divided total study population into PLA2R-related and PLA2R-unrelated subgroup. We found no IgG subclass switch from IgG1 to IgG4 in PLA2R-related or unrelated subgroup. In PLA2R-related subgroup, IgG4 was the predominant IgG subclass of all stages. Our results were identical to other Asia studies reported by Hayashi et al. [19] and Dong et al. [20]. For PLA2R-unrelated group, our data indicated that it was a heterogeneous subgroup. Several studies described potential autoantigens such as aldose reductase, SOD2, thrombospondin type

### Table 2: Comparison of clinical characteristics between two subgroups.

| Characteristic | PLA2R-related ($n = 132$) | PLA2R-unrelated ($n = 25$) | $P$ value |
|---------------|--------------------------|---------------------------|---------|
| Age (yrs), M (P25, P75) | 51 (37, 58) | 49 (40.5, 57.5) | 0.867 |
| Men, n (%) | 73 (55%) | 16 (64%) | 0.421 |
| Alb (g/L), M (P25, P75) | 28 (23, 32) | 25 (20.5, 35) | 0.378 |
| 24hUP (g/d), M (P25, P75) | 4.7 (2.3, 7.3) | 5.4 (1.8, 8.6) | 0.878 |
| Scr (μmol/L), M (P25, P75) | 73 (61, 87) | 72 (63, 86) | 0.859 |
| EM stage number, (%) | | | 0.386 |
| 1 | 31 (24%) | 7 (28%) | 0.867 |
| 2 | 74 (56%) | 10 (40%) | |
| 3 | 12 (9%) | 4 (16%) | 0.421 |
| 4 | 15 (11%) | 4 (16%) | |

### Table 3: Prevalence of serum anti-PLA2R antibody and glomerular staining of PLA2R.

| Serum anti-PLA2R antibody | PLA2R on glomerular | Total |
|---------------------------|---------------------|-------|
| +                         | 75                  | 119   |
| -                         | 13                  | 38    |
| Total                     | 88                  | 157   |

| IF intensity of IgG subclass staining | IgG1 | IgG2 | IgG3 | IgG4 |
|---------------------------------------|-----|-----|-----|-----|
| PLA2R-related | [2.5] | [2.0] | [1.5] | [3.0] |
| PLA2R-unrelated | [2.5] | [2.0] | [1.5] | [3.0] |

Figure 2: The fluorescence intensity of IgG subclasses compared in PLA2R-related and PLA2R-unrelated group.

Figure 3: The fluorescence intensity of IgG4 compared in PLA2R-related and PLA2R-unrelated group.

We did not discover IgG subclass switch from IgG1 to IgG4 in IMN as reported by Huang et al. [4]. The pre/co-rate of IgG4 in EM stage 1 was obviously high in our study than that in Huang et al.’s study (89% vs. 55%). Three possible reasons might contribute to the discrepancy. Firstly, the different inclusion criteria could bring selection bias. The clinical data were not provided in Huang et al.’s work. We failed to analyze the difference of two study populations. Secondly, the discrepancy might come from the distribution of EM stages between two studies ($\chi^2 = 24.85, P < 0.001$). The difference mainly existed in early stages ($n = 38, 24.2\%$ vs. $n = 58, 50.9\%$ in stage 1) and middle stages ($n = 100, 63.7\%$ vs. $n = 39, 34.2\%$ in stages 2-3) between our data and Huang et al.’s. Thirdly, the definition of early EM stage (stage 1) was different. Huang et al. emphasized they separated the “true” stage 1 by redefining it as electronic dense absent between subepithelial. Our cohort might include more advanced patients of stage 1. However, the pre/co-rate of IgG4 was comparable between stages 1 and 2 (89% vs. 94%) in our study, even in PLA2R-related group that was higher of stage 1 than that of stage 2 (97% vs. 95%). It was unlikely that the discrepancy of EM stage definition gave rise to the gap on pre/co-rate of IgG4 in stage 1 between two studies. We assumed the discrepancy just reflected ethnic differences [18]. Huang et al. provided no serum or pathological profiles of PLA2R. To further explore IgG subtype switch of different antigens, we divided total study population into PLA2R-related and PLA2R-unrelated subgroup.

We found no IgG subclass switch from IgG1 to IgG4 in PLA2R-related or unrelated subgroup. In PLA2R-related subgroup, IgG4 was the predominant IgG subclass of all stages. Our results were identical to other Asia studies reported by Hayashi et al. [19] and Dong et al. [20]. For PLA2R-unrelated group, our data indicated that it was a heterogeneous subgroup. Several studies described potential autoantigens such as aldose reductase, SOD2, thrombospondin type
1 domain-containing 7A (THSD7A), exostosin1/exostosin2 (EXT1/2), and neural epidermal growth factor-like 1 protein (NELL-1) besides PLA2R [21–25]. The IgG subtype distributions of those antigens were not explicitly discussed except THSD7A [26]. In the early stage of EXT1/2 positive MN, the pathological and clinical manifestation might present as

**Figure 4:** Predominant/codominant deposits of IgG subclasses in different EM stages in PLA2R-related and PLA2R-unrelated subgroup.

**Table 4:** Predominance/codominance and EM stage in PLA2R-related and PLA2R-unrelated subgroup.

| IgG subclass | Pathological stage | Predominance or codominance | Chi-square test | Linear-by-linear association test |
|--------------|--------------------|-----------------------------|----------------|---------------------------------|
| PLA2R-related | I (n = 31) | II (n = 74) | III (n = 12) | IV (n = 15) | 0.767 | 0.768 |
| IgG1 | 12 (39%) | 37 (50%) | 5 (42%) | 7 (47%) | 0.493 | 0.434 |
| IgG2 | 1 (3%) | 6 (8%) | 0 (0%) | 2 (13%) | 0.087 | 0.013 |
| IgG3 | 11 (35%) | 14 (13%) | 1 (8%) | 1 (7%) | 0.469 | 0.380 |
| IgG4 | 30 (97%) | 70 (95%) | 12 (100%) | 13 (87%) | 0.331 | 0.835 |
| PLA2R-unrelated | I (n = 7) | II (n = 10) | III (n = 4) | IV (n = 4) | 0.640 | 0.574 |
| IgG1 | 3 (43%) | 5 (50%) | 1 (25%) | 3 (75%) | NA | NA |
| IgG2 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | NA |
| IgG3 | 3 (43%) | 1 (10%) | 3 (75%) | 1 (25%) | 0.081 | 1.000 |
| IgG4 | 4 (57%) | 9 (90%) | 3 (75%) | 2 (50%) | 0.331 | 0.835 |

NA: not available.
PLA2R-negative IMN until the secondary cause revealed [24]. Researchers recently discovered that anti-NELL-1 could also induce IMN but prevailing with IgG1. The pathological feature of PLA2R-unrelated subgroup should be investigated separately according to different autoantigens in future research.

The novelty of our study was that we distinguished PLA2R-related group from IMN and found out IgG subclasses distribution of PLA2R-related/PLA2R-unrelated IMN among different EM stages. The declined IgG3 deposition with EM stage in PLA2R-related subgroup might suggest a new perspective to understand the disease. The limitations of our study must be mentioned. Firstly, our profile of IgG subclasses might not well represent the population due to the limited sample size, especially stage 3-4. Secondly, we chose indirect IF to measure IgG subclasses on glomerular. The method was sensitive but might cause false positives. Thirdly, we did not screen other autoantibody of MN because of limited serum or tissue sample. It would be interesting to study glomerular IgG subclass of PLA2R-unrelated MN population by increasing the sample size.

5. Conclusions

IgG3 showed a declining trend in PLA2R-related IMN. We did not observe the glomerular IgG subclass switch from IgG1 to IgG4 in either total IMN patients or subgroups.

Data Availability

Comprehensive data are presented in the manuscript, table, and figures. The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

HC and CL contributed equally to this work. The contributions of each co-author are as follows. HC, CL, and HL are responsible for the research conception and design; HC for the analysis and interpretation of data; HC and CL for drafting the manuscript; CL and HL for the revision; YW, HL, and LD for the pathology diagnosis and providing intellectual content of critical importance to the work; YL, XY, and YH for the renal pathology slide preparing and serum detecting; and HL, LC, and XL for the final approval of the version to be published.

Acknowledgments

The data input by Bo-na Zhai is greatly appreciated. This study was supported by the PUMCH Science Fund for Junior Faculty (No. pumch-2016-2.21).

References

[1] P. Ronco and H. Debiec, “Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care,” Lancet, vol. 385, no. 9981, pp. 1983–1992, 2015.

[2] C. Ponticelli and R. J. Glassock, “Glomerular diseases: membranous nephropathy—a modern view,” Clinical Journal of the American Society of Nephrology, vol. 9, pp. 609–616, 2014.

[3] L. H. Beck Jr., R. G. Bonegio, G. Lambeau et al., “M-type phospholipase A2Receptor as target antigen in idiopathic membranous nephropathy,” New England Journal of Medicine, vol. 361, no. 1, pp. 11–21, 2009.

[4] C. C. Huang, A. Lehman, A. Albawardi et al., “IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression,” Modern Pathology, vol. 26, no. 6, pp. 799–805, 2013.

[5] K. Hihara, M. Iyoda, S. Tachibana et al., “Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy,” PLoS One, vol. 11, no. 6, p. e0158154, 2016.

[6] A. G. Kattah, M. P. Alexander, A. Angioi et al., “The anti-PLA2R antibody in membranous nephropathy: a modern view,” Modern Pathology, vol. 17, no. 12, pp. 1555–1563, 2004.

[7] P. D. Walker, T. Cavallo, and S. M. Bonsib, “Practice guidelines for the renal biopsy,” Modern Pathology, vol. 17, no. 12, pp. 1555–1563, 2004.

[8] P. D. Walker, “The renal biopsy,” Archives of Pathology & Laboratory Medicine, vol. 133, no. 2, pp. 181–188, 2009.

[9] T. Ehrenreich and J. Chung, “Pathology of membranous nephropathy,” Pathology Annual, vol. 3, pp. 145–186, 1968.

[10] A. M. Colins and K. J. Jackson, “A temporal model of human IgE and IgG antibody function,” Frontiers in Immunology, vol. 4, p. 235, 2013.

[11] A. W. Chung, T. K. Ho, P. Hanson-Manful et al., “Systems immunology reveals a linked IgG3-C4 response in patients with acute rheumatic fever,” Immunology and Cell Biology, vol. 98, no. 1, pp. 12–21, 2020.

[12] J. Li, Z. Cui, J. Long et al., “Primary glomerular nephropathy among hospitalized patients in a national database in China,” Nephrology, Dialysis, Transplantation, vol. 33, pp. 2173–2181, 2018.

[13] X. Xu, G. Wang, N. Chen et al., “Long-term exposure to air pollution and increased risk of membranous nephropathy in China,” Journal of the American Society of Nephrology, vol. 27, no. 12, pp. 3739–3746, 2016.

[14] A. E. Van de Logt, M. Fresquet, J. F. Wetzel, and P. Brenchley, “The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery,” Kidney International, vol. 96, no. 6, pp. 1292–1302, 2019.

[15] H. Debiec, M. Hanoy, A. Francois et al., “Recurrent membranous nephropathy in an allograft caused by IgG3x targeting the PLA2 receptor,” Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 1949–1954, 2012.

[16] B. Seitz-Polksi, G. Dolla, C. Payré et al., “Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 27, pp. 1517–1533, 2016.

[17] J. M. Hofstra, H. Debiec, C. D. Short et al., “Antiphospholipase A2 receptor antibody titer and subclass in idiopathic
membranous nephropathy,” *Journal of the American Society of Nephrology*, vol. 23, no. 10, pp. 1735–1743, 2012.

[18] W. Schlumberger, N. Hornig, S. Lange et al., “Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1,” *Autoimmunity Reviews*, vol. 13, no. 2, pp. 108–113, 2014.

[19] N. Hayashi, S. Akiyama, H. Okuyama et al., “Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese,” *Clinical and Experimental Nephrology*, vol. 19, no. 5, pp. 797–803, 2015.

[20] H. R. Dong, Y. Y. Wang, X. H. Cheng et al., “Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy,” *PLoS One*, vol. 11, no. 5, article e0156263, 2016.

[21] M. Prunotto, M. L. Carnevali, G. Candiano et al., “Autoimmunity in membranous nephropathy targets aldose reductase and SOD2,” *Journal of the American Society of Nephrology*, vol. 21, no. 3, pp. 507–519, 2010.

[22] M. Bruschi, M. L. Carnevali, C. Murtas et al., “Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens,” *Journal of Proteomics*, vol. 74, no. 10, pp. 2008–2017, 2011.

[23] N. M. Tomas, L. H. Beck Jr., C. Meyer-Schwesinger et al., “Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” *The New England Journal of Medicine*, vol. 371, no. 24, pp. 2277–2287, 2014.

[24] S. Sethi, B. J. Madden, H. Dabiec et al., “Exostosin 1/exostosin 2-associated membranous nephropathy,” *Journal of the American Society of Nephrology*, vol. 30, no. 6, pp. 1123–1136, 2019.

[25] S. Sethi, H. Debiec, B. Madden et al., “Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy,” *Kidney International*, vol. 97, no. 1, pp. 163–174, 2020.

[26] N. M. Tomas, E. Hoxha, A. T. Reinicke et al., “Auto-antibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy,” *The Journal of Clinical Investigation*, vol. 126, pp. 2519–2532, 2016.